PagSeguro looks like a payments company, but the bigger story is a growing digital bank inside it that could become the main profit engine if its lending keeps expanding without blowing up. The catch is that loan losses, tougher competition, and shifting rules in Brazil could turn that same push into the thing that hurts it most.Read more

This small Canadian company owns stakes in two US specialty surgery hospitals, but a big part of the cash flow goes to its physician partners. The real question is whether management uses its large cash pile to buy back shares, pay a special dividend, or sell a hospital—or lets the discount linger.Read more

Arrow, a small Colombian oil producer, sits on a growing cash pile with no debt, but its biggest upside hinges on a make-or-break permit decision and whether new wells keep delivering. See why this could be a time-limited trade rather than a long-term hold, and what could leave the shares stuck for months even if the company stays healthy.Read more

A recent rule change lowers a big barrier for doctors to offer biote’s hormone pellet treatment, just as the company rebuilds after a supplier recall shook confidence. The upside hinges on whether new sales hires can grow the doctor network fast enough while quality and debt risks stay under control.Read more

Columbus McKinnon is trying to turn a big acquisition into a steadier, more repeat-buy parts business, but the plan hinges on a tough integration and cross-selling across regions. The catch is the company carries heavy debt, so a slowdown or missteps could quickly overwhelm the upside.Read more